Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Graham F. Smith"'
Autor:
Joerg Schlingemann, Michael J. Burns, David J. Ponting, Carolina Martins Avila, Naiffer E. Romero, Mrunal A. Jaywant, Graham F. Smith, Ian W. Ashworth, Stephanie Simon, Christoph Saal, Andrzej Wilk
Publikováno v:
Journal of Pharmaceutical Sciences. 112:1287-1304
This article reports the outcome of an in silico analysis of more than 12,000 small molecule drugs and drug impurities, identifying the nitrosatable structures, assessing their potential to form nitrosamines under relevant conditions and the challeng
Autor:
Olga Obrezanova, Anton Martinsson, Tom Whitehead, Samar Mahmoud, Andreas Bender, Filip Miljković, Piotr Grabowski, Ben Irwin, Ioana Oprisiu, Gareth Conduit, Matthew Segall, Graham F. Smith, Beth Williamson, Susanne Winiwarter, Nigel Greene
Publikováno v:
Molecular Pharmaceutics. 19:1488-1504
Animal pharmacokinetic (PK) data as well as human and animal in vitro systems are utilized in drug discovery to define the rate and route of drug elimination. Accurate prediction and mechanistic understanding of drug clearance and disposition in anim
Autor:
Rodrigo Aguilar, Kerrie B. Spencer, Barry Kesner, Noreen F. Rizvi, Maulik D. Badmalia, Tyler Mrozowich, Jonathan D. Mortison, Carlos Rivera, Graham F. Smith, Julja Burchard, Peter J. Dandliker, Trushar R. Patel, Elliott B. Nickbarg, Jeannie T. Lee
Publikováno v:
Nature. 604:160-166
Autor:
Helen L. Lightfoot, Graham F. Smith
Publikováno v:
British Journal of Pharmacology.
Autor:
Powe, Rod
Publikováno v:
Journal of Industrial Relations; September 1988, Vol. 30 Issue: 3 p468-470, 3p
Autor:
Hongbin Yang, Olga Obrezanova, Amy Pointon, Will Stebbeds, Jo Francis, Kylie A. Beattie, Peter Clements, James S. Harvey, Graham F. Smith, Andreas Bender
Publikováno v:
Toxicology and applied pharmacology. 459
Functional changes to cardiomyocytes are undesirable during drug discovery and identifying the inotropic effects of compounds is hence necessary to decrease the risk of cardiovascular adverse effects in the clinic. Recently, approaches leveraging cal
Autor:
Peter S.R. Wright, Graham F. Smith, Katharine A. Briggs, Robert Thomas, Gareth Maglennon, Paulius Mikulskis, Melissa Chapman, Nigel Greene, Benjamin U. Phillips, Andreas Bender
Publikováno v:
Regulatory Toxicology and Pharmacology. 138:105309
Virtual Control Groups (VCGs) based on Historical Control Data (HCD) in preclinical toxicity testing have the potential to reduce animal usage. As a case study we retrospectively analyzed the impact of replacing Concurrent Control Groups (CCGs) with
Autor:
Peter S.R. Wright, Katharine A. Briggs, Robert Thomas, Graham F. Smith, Gareth Maglennon, Paulius Mikulskis, Melissa Chapman, Nigel Greene, Benjamin U. Phillips, Andreas Bender
Publikováno v:
Regulatory Toxicology and Pharmacology. 138:105308
Preclinical inter-species concordance can increase the predictivity of observations to the clinic, potentially reducing drug attrition caused by unforeseen adverse events. We quantified inter-species concordance of histopathological findings and targ
Autor:
Graham F, Smith
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2390
The use of artificial intelligence methods in drug safety began in the early 2000s with applications such as predicting bacterial mutagenicity and hERG inhibition. The field has been endlessly expanding ever since and the models have become more comp
Autor:
William, McCoull, Scott, Boyd, Martin R, Brown, Muireann, Coen, Olga, Collingwood, Nichola L, Davies, Ann, Doherty, Gary, Fairley, Kristin, Goldberg, Elizabeth, Hardaker, Guang, He, Edward J, Hennessy, Philip, Hopcroft, George, Hodgson, Anne, Jackson, Xiefeng, Jiang, Ankur, Karmokar, Anne-Laure, Lainé, Nicola, Lindsay, Yumeng, Mao, Roshini, Markandu, Lindsay, McMurray, Neville, McLean, Lorraine, Mooney, Helen, Musgrove, J Willem M, Nissink, Alexander, Pflug, Venkatesh Pilla, Reddy, Philip B, Rawlins, Emma, Rivers, Marianne, Schimpl, Graham F, Smith, Sharon, Tentarelli, Jon, Travers, Robert I, Troup, Josephine, Walton, Cheng, Wang, Stephen, Wilkinson, Beth, Williamson, Jon, Winter-Holt, Dejian, Yang, Yuting, Zheng, Qianxiu, Zhu, Paul D, Smith
Publikováno v:
Journal of medicinal chemistry. 64(18)
Inhibition of Mer and Axl kinases has been implicated as a potential way to improve the efficacy of current immuno-oncology therapeutics by restoring the innate immune response in the tumor microenvironment. Highly selective dual Mer/Axl kinase inhib